Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when NOVT files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsNovanta to acquire Runway Buyer for $1.45B, financing via cash, debt, and new equity
Filed June 9, 2026 · Period ending June 8, 2026 · ~1 min read
Key Changes
-
high
Novanta signed definitive agreement to acquire all equity interests in Runway Buyer, LLC for $1.2B cash at closing plus $250M milestone payment due January 2027, totaling $1.45B.
Item 1.01: Equity Purchase Agreement verify on EDGAR → -
high
Transaction will be financed through existing cash, credit facility borrowings, and proceeds from a new equity issuance announced the same day, indicating significant capital raise alongside debt.
Item 1.01: Transaction financing verify on EDGAR → -
high
Credit agreement amended to allow leverage up to 4.5x for four quarters post-closing and relaxed coverage ratio to 1.0x, with 0.25% higher interest rate when leverage exceeds 3.75x.
Item 1.01: Credit Amendment verify on EDGAR → -
medium
Closing expected within approximately $1,200,000,000 five months, subject to HSR antitrust clearance and standard conditions including no material adverse effect on target.
Item 1.01: Closing conditions verify on EDGAR → -
medium
Company disclosed integration risks including potential failure to realize synergies, difficulties retaining key personnel at acquired business, and financing execution challenges.
Item 7.01: Forward-looking statements verify on EDGAR →
Summary
Novanta announced a major acquisition, agreeing to purchase all equity interests in Runway Buyer, LLC for $1.45 billion—$1.2 billion at closing plus a $250 million milestone payment due in seven months.
The deal represents a significant expansion requiring substantial financing through a three-pronged approach: existing cash, credit facility borrowings, and a newly announced equity issuance that will dilute current shareholders. The financing structure reveals the deal's leverage impact.
Novanta amended its credit agreement to accommodate higher debt levels, allowing leverage ratios up to 4.5x for four quarters post-closing and temporarily relaxing its fixed charge coverage ratio to just 1.0x. The company will also pay higher interest rates (an additional 0.25%) when leverage exceeds 3.75x. These covenant changes suggest Novanta will operate with elevated financial risk during the integration period. Retail investors should watch for three things: details on the equity issuance size and pricing (which determines dilution), the HSR antitrust review timeline, and management's disclosure of Runway Buyer's financials and strategic rationale. The company has acknowledged integration risks and potential difficulties realizing anticipated synergies, making execution critical to justifying the substantial capital commitment.
Section-by-Section Diff
Event · Item 1.01 — Entry into a Material Definitive Agreement
Item 1.01 — Entry into a Material Definitive Agreement filed; see Key Changes for terms.
Added in current filing · verify on EDGAR →
On June 8, 2026, Novanta Inc., a Canadian corporation (the “Company”), Novanta Medical Technologies Corp., a Delaware corporation and an indirect subsidiary of the Company (“Buyer”), Novanta Corporation, a Michigan corporation (“Intermediate Parent”, and together with the Company and the Buyer, the “Buyer Parties”), Runway Midco, LLC, a Delaware limited liability company (“Seller”), and Runway Buyer, LLC, a Delaware limited liability company and direct wholly owned subsidiary of Seller (“Runway Buyer”), entered into an Equity Purchase Agreement (the “Purchase Agreement”), pursuant to which Buyer will acquire from Seller all of the issued and outstanding limited liability company interests (the “Purchased Interests”) of Runway Buyer (the “Transaction”).
Novanta entered into a definitive agreement to acquire all equity interests in Runway Buyer, LLC from Runway Midco, LLC. The transaction represents a significant acquisition that will expand Novanta's business operations through the purchase of all outstanding interests in the target company.
Added in current filing · verify on EDGAR →
The Transaction will be financed through a combination of cash on hand, the Company’s existing credit facilities available under the Credit Agreement (as defined below) and proceeds from the Company’s equity issuance announced today.
Novanta will fund the $1.45 billion acquisition using three sources: existing cash, borrowings under its credit facilities, and proceeds from a new equity issuance announced the same day. This financing mix indicates the company is using both balance sheet resources and new capital to complete the deal.
Added in current filing · verify on EDGAR →
The Closing is subject to satisfaction or waiver of certain conditions, including, among other things, (a) the absence of any law, order or injunction by any governmental entity of competent jurisdiction preventing the completion of the Transaction or making the completion of the Transaction illegal, (b) the expiration or termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (the “HSR Act”), without the imposition of an unacceptable condition, (c) subject to certain exceptions, the accuracy of representations and warranties with respect to the Buyer Parties, Runway Buyer and the Seller, (d) compliance in all material respects by the Buyer Parties, Runway Buyer and the Seller with their respective covenants contained in the Purchase Agreement and (e) the absence of any Material Adverse Effect (as defined in the Purchase Agreement) with respect to Runway Buyer.
The transaction closing requires standard conditions including HSR antitrust clearance, no legal prohibitions, accuracy of representations and warranties, covenant compliance, and no material adverse effect on the target. The agreement allows up to 150 days to complete the transaction, indicating an expected closing timeline of approximately $1,200,000,000 five months from signing.
Event · Item 7.01 — Regulation FD Disclosure
Novanta announced a transaction via press release and conference call, with completion subject to regulatory approvals and financing.
Added in current filing · verify on EDGAR →
On June 9, 2026, the Company issued a press release announcing the Transaction.
Novanta disclosed a transaction on June 9, 2026, through a press release and conference call. The 8-K does not specify the nature of the transaction, but forward-looking statements reference regulatory approvals, financing, integration of 'Runway Buyer and its subsidiaries,' and anticipated benefits and synergies, suggesting an acquisition.
Added in current filing · verify on EDGAR →
the expected timing and completion of the transaction, the ability of the parties to satisfy the conditions precedent to consummation of the proposed transaction, including the ability to secure the applicable regulatory approvals on the terms expected, at all or in a timely manner, the anticipated benefits and synergies of the transaction, the expected financing of the transaction statements
The transaction requires regulatory approvals and financing, with no guarantee of completion on the anticipated timeline or at all. The company warns that anticipated benefits and synergies may not be realized and that integration of the acquired business may not be successful.
Added in current filing · verify on EDGAR →
the risk that the business of Runway Buyer and its subsidiaries may not be integrated successfully; risks relating to the financing for the transaction; risks relating to the effect of the announcement of the proposed transaction on the ability of Runway Buyer and its subsidiaries to retain and hire key personnel and maintain relationships with its key business partners and customers
The company identifies specific risks including unsuccessful integration of Runway Buyer's business, financing challenges, and potential difficulties retaining key personnel and customer relationships at the acquired entity. These operational risks could materially affect the transaction's success.
Event · Item 9.01 — Financial Statements and Exhibits
Novanta disclosed an equity purchase agreement and credit facility amendment, suggesting a material acquisition or divestiture transaction.
Added in current filing · verify on EDGAR →
Equity Purchase Agreement, dated as of June 8, 2026, by and among Novanta Medical Technologies Corp., Novanta Corporation, Novanta Inc., Runway Midco, LLC and Runway Buyer, LLC
Novanta entered into an equity purchase agreement on June 8, 2026 involving multiple Novanta entities and two Runway entities (Runway Midco, LLC and Runway Buyer, LLC). The structure suggests either an acquisition by Novanta or a divestiture of a business unit to the Runway entities, though the direction and financial terms are not disclosed in the 8-K body.
Added in current filing · verify on EDGAR →
Third Amendment to Fourth Amended and Restated Credit Agreement, dated as of June 8, 2026
Novanta amended its credit facility on the same date as the equity purchase agreement. Credit amendments typically accompany material transactions to adjust borrowing capacity, covenants, or terms to accommodate the deal structure or financing needs. The specific changes to the credit agreement are not detailed in the 8-K body.
Added in current filing · verify on EDGAR →
Press Release issued June 9, 2026 by the Company
Novanta issued a press release and held an investor conference call on June 9, 2026, indicating the company is publicly disclosing details of the transaction to investors. These materials likely contain financial terms, strategic rationale, and management commentary not included in the 8-K body itself.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jun 9, 2026 · How we verify